Tick Antivenom

MATERIAL SAFETY DATA SHEET

IMPORTANT NOTICE This Material Safety Data Sheet (MSDS) is prepared by CSL Limited in accordance with the Australian National Occupational Health & Safety Commission National Code of Practice for the Preparation of Material Safety Data Sheets [NOHSC:2011(2003)]. The information contained herein must not be altered or deleted. Additional information may be appended to the MSDS, but it must be marked clearly to indicate that it is not part of the original.

1. IDENTIFICATION OF THE MATERIAL AND SUPPLIER

Product Name Tick Antivenom

Other Names *Ixodes holocyclus* Antivenom

Manufacturer's Product Code 05051301

Use For the treatment of patients who show evidence of paralysis as a result of envenoming by a tick.

Adrenaline should always be readily available whenever the injection is given.

Supplier Name CSL Limited (ABN 99 051 588 348)

Address 45 Poplar Road, Parkville, Victoria 3052, Australia

Telephone +61 03 9389 1911

Emergency Telephone 03 9389 1984 (24hr)

2. HAZARDS IDENTIFICATION

Not classified as hazardous according to the criteria of NOHSC
Not classified as a dangerous good by the criteria of the ADG Code

3. COMPOSITION/INFORMATION ON INGREDIENTS

Name:	*CAS number:*	*Proportion:*
Canine plasma protein	-	Approx. 4% w/v
Sodium Chloride	7647-14-5	0.8% w/v
Glycine	50-40-6	0.4% w/v
Water	-	up to 100%

4. FIRST AID MEASURES

Accidental Injection If allergic reaction occurs seek immediate medical attention.

Eye Separate eyelids with fingers. Flush with copious amounts of water for at least 15 minutes.

Swallowed DO NOT induce vomiting. If exposed subject is fully conscious, wash out mouth with water and give plenty of water to drink. If hypersensitivity occurs, seek immediate medical attention.

Skin Remove contaminated clothing. Flush area with copious amounts of water.

Inhaled Move exposed person to fresh air. If necessary administer medical oxygen by trained personnel. If allergic reaction occurs seek immediate medical attention.

First Aid Facilities Adrenaline should always be readily available whenever the injection is given.

Aggravated Medical Conditions In individuals hypersensitive to canine plasma protein, may precipitate an acute allergic reaction.

Symptoms and signs of anaphylaxis include pallor, rapid heart rate, shortness of breath, skin rash, hives, coughing, bronchospasm or loss of consciousness.

See product information leaflet for information regarding pre-existing conditions.

Advice To Doctor Treat symptomatically. Cases of anaphylaxis may require treatment with adrenaline, oxygen, intravenous steroids and airway management including intubation.

The sooner the onset of an allergic reaction, the more severe the reaction.

5. FIRE FIGHTING MEASURES

Fire/Explosion Hazard Non-combustible. Not considered a significant fire risk.

Fire Extinguishing Media No restrictions.

Hazchem Code None allocated.

6. ACCIDENTAL RELEASE MEASURES

Minor Spills

- Wear protective gloves and safety glasses.
- Remove broken glass.
- Take care to avoid excessive dust during clean up.
- If powder is present wear a minimum P1 filter grade dust mask.
- Clean up spill immediately (if product has been reconstituted, absorb using paper towels.
- Place spilled material in clean, dry, sealed container for disposal.
- Decontaminate area with 1% sodium hypochlorite in water.

Major Spills

- Wear protective gloves and safety glasses.
- Contain and absorb spills using earth, sand or inert absorbent.
- Remove broken glass.
- Take care to avoid excessive dust during clean up.
- If powder is present wear a minimum P1 filter grade dust mask.
- Collect residues and seal in labelled drums for disposal.
- Decontaminate area with 1% sodium hypochlorite in water.

7. HANDLING AND STORAGE

- Transport and store at 2 to 8 degrees C (do not freeze).
- Protect from light.
- Store as per Schedule 4 pharmaceutical.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Exposure Standards No exposure limits set by NOHSC or ACGIH

Engineering Controls None under normal operating conditions.

Personal Protection For good infection control, gloves should be worn when administering an injection.

The local concentration of material, quantity and conditions of use determine the type of personal protective equipment required. For further information, consult your Occupational Health and Safety Adviser.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance Freeze dried powder in a glass vial.

Odour Slight odour

pH 6.2-7

Boiling Point/Melting Point Not determined

Vapour Pressure Not determined

Vapour Density Not determined

Specific Gravity Not determined

Flashpoint Not flammable

Flammability Limits Not flammable

Solubility in Water Miscible.

10. STABILITY AND REACTIVITY

Reactivity Not known to be incompatible with other materials.

Stability Stable under anticipated storage and handling conditions (refer section 7).

Decomposition Products Not determined

11. TOXICOLOGICAL INFORMATION

Special Warning: When medicinal products prepared from animal plasma are administered, infectious diseases due to the transmission of infective agents cannot be totally excluded. This applies to pathogens of hitherto unknown origin. This possibility must always be considered and should be conveyed, whenever possible, to patients who may receive the product. Historically there have been no known recorded cases of transmission of viruses by this product.

Accidental Injection May cause redness at injection site. In individuals hypersensitive to canine plasma protein, may precipitate an acute allergic reaction.

Symptoms and signs of anaphylaxis include pallor, rapid heart rate, shortness of breath, skin rash, hives, coughing, bronchospasm or loss of consciousness.

Eye May cause irritation.

Swallowed May cause irritation of the gastro-intestinal tract. In hypersensitive individuals, may precipitate an acute allergic reaction (anaphylaxis). Severe allergic reactions will usually occur within the first few hours of ingestion, see Acute Health Effects: Accidental Injection.

Skin Nil in non-allergic individuals. May cause irritation in hypersensitive individuals.

Inhaled May cause irritation of the respiratory tract. In hypersensitive individuals, may precipitate an acute allergic reaction (anaphylaxis). Severe allergic reactions will usually occur within the first few hours of inhalation, see Acute Health Effects: Accidental Injection.

Chronic Health Effects Chronic or repeated exposure may produce reactions in persons sensitive to canine plasma proteins.

12. ECOLOGICAL INFORMATION

- No data available.
- For good environmental practice avoid discharge to waterways.

13. DISPOSAL CONSIDERATIONS

- In accordance with state land and waste management authority.
- Use an on site licensed incinerator, if permitted by licence. Alternatively, dispose via a licensed commercial incinerator.

14. TRANSPORT INFORMATION

UN Number None allocated

DG Class None allocated

Subsidiary Risk None allocated

Packing Group None allocated

Hazchem Code None allocated

15. REGULATORY INFORMATION

Poisons Schedule Number Schedule 4 (S4) – Prescription only medicine

16. OTHER INFORMATION

Last Revised 10 November 2009

Reason for Revision Reissue of MSDS.

Abbreviations

NOHSC – National Occupational Health and Safety Commission (please note NOHSC information can be sourced from www.ascc.gov.au)
ACGIH – American Conference of Governmental Industrial Hygienists
ADG Code – Australian Dangerous Goods Code
UN Number – United Nations Number
DG Class – Dangerous Goods Class
CAS Number – Chemical Abstract Service Number

Contact Point

Company Contact:	+61 3 9389 1984 (24hr)
Australian Poisons Information Centre, 24 hour service:	13 11 26
Australian Police, Fire Brigade or Ambulance:	000
New Zealand Poisons Information Centre, 24 hour service:	(03) 4747 000
New Zealand Police, Fire Brigade or Ambulance:	111